1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Aptamer Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Aptamer Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Aptamer Market Analysis and Forecast, by Material
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Material, 2023–2031
6.3.1. Nucleic Acid Aptamer
6.3.2. Peptide Aptamer
6.4. Market Attractiveness, by Material
7. Aptamer Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2023–2031
7.3.1. Research
7.3.2. Diagnostic
7.3.3. Therapeutics
7.3.4. Others
7.3.5. 7.4 Market Attractiveness, by Application
8. Global Aptamer Market Analysis and Forecast, by Technique
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technique, 2023–2031
8.3.1. SELEX Technique
8.3.2. Others (MARAS, etc.)
8.4. Market Attractiveness, by Technique
9. Global Aptamer Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Aptamer Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Material, 2023–2031
10.2.1. Nucleic Acid Aptamer
10.2.2. Peptide Aptamer
10.3. Market Attractiveness, by Material
10.4. Market Value Forecast, by Application, 2023–2031
10.4.1. Research
10.4.2. Diagnostic
10.4.3. Therapeutics
10.4.4. Others
10.5. Market Attractiveness, by Application
10.6. Market Value Forecast, by Technique, 2023–2031
10.6.1. SELEX Technique
10.6.2. Others (MARAS, etc.)
10.7. Market Attractiveness, by Technique
10.8. Market Value Forecast, by Country, 2022–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Material
10.9.2. By Application
10.9.3. By Technique
10.9.4. By Country
11. Europe Aptamer Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Material, 2023–2031
11.2.1. Nucleic Acid Aptamer
11.2.2. Peptide Aptamer
11.3. Market Attractiveness, by Material
11.4. Market Value Forecast, by Application, 2023–2031
11.4.1. Research
11.4.2. Diagnostic
11.4.3. Therapeutics
11.4.4. Others
11.5. Market Attractiveness, by Application
11.6. Market Value Forecast, by Technique, 2023–2031
11.6.1. SELEX Technique
11.6.2. Others (MARAS, etc.)
11.7. Market Attractiveness, by Technique
11.8. Market Value Forecast, by Country/Sub-region, 2022–2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Material
11.9.2. By Application
11.9.3. By Technique
11.9.4. By Country/Sub-region
12. Asia Pacific Aptamer Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Material, 2023–2031
12.2.1. Nucleic Acid Aptamer
12.2.2. Peptide Aptamer
12.3. Market Attractiveness, by Material
12.4. Market Value Forecast, by Application, 2023–2031
12.4.1. Research
12.4.2. Diagnostic
12.4.3. Therapeutics
12.4.4. Others
12.5. Market Attractiveness, by Application
12.6. Market Value Forecast, by Technique, 2023–2031
12.6.1. SELEX Technique
12.6.2. Others (MARAS, etc.)
12.7. Market Attractiveness, by Technique
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Material
12.9.2. By Application
12.9.3. By Technique
12.9.4. By Country/Sub-region
13. Latin America Aptamer Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Material, 2023–2031
13.2.1. Nucleic Acid Aptamer
13.2.2. Peptide Aptamer
13.3. Market Attractiveness, by Material
13.4. Market Value Forecast, by Application, 2023–2031
13.4.1. Research
13.4.2. Diagnostic
13.4.3. Therapeutics
13.4.4. Others
13.5. Market Attractiveness, by Application
13.6. Market Value Forecast, by Technique, 2023–2031
13.6.1. SELEX Technique
13.6.2. Others (MARAS, etc.)
13.7. Market Attractiveness, by Technique
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Material
13.9.2. By Application
13.9.3. By Technique
13.9.4. By Country/Sub-region
14. Middle East & Africa Aptamer Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Material, 2023–2031
14.2.1. Nucleic Acid Aptamer
14.2.2. Peptide Aptamer
14.3. Market Attractiveness, by Material
14.4. Market Value Forecast, by Application, 2023–2031
14.4.1. Research
14.4.2. Diagnostic
14.4.3. Therapeutics
14.4.4. Others
14.5. Market Attractiveness, by Application
14.6. Market Value Forecast, by Technique, 2023–2031
14.6.1. SELEX Technique
14.6.2. Others (MARAS, etc.)
14.7. Market Attractiveness, by Technique
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Material
14.9.2. By Application
14.9.3. By Technique
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AM Biotech
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Aptagen, LLC
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Aptamer Group
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Aptamer Science, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pfizer Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Base Pair Biotechnologies
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. CD Genomics
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. NeoVentures Biotechnology Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. NAXXON Pharma
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Aptus Biotech
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. TriLink Bio Technologies, LLC
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer